Circulating Tumor DNA May Help Predict Recurrence in Patients with Early Triple-Negative Breast Cancer
Study also indicated that a lack of ctDNA may signal improved outcomes for patients SAN ANTONIO — The presence...
Search/Filter
Loading...
Residual Cancer Burden Can Predict Outcomes for Patients With Any Breast Cancer Type
SAN ANTONIO — A large meta-analysis of breast cancer patients showed that residual cancer burden after neoadjuvant chemotherapy is...
Oral Paclitaxel Yielded Better Outcomes Than Intravenous Paclitaxel for Metastatic Breast Cancer Patients in Phase III Trial
SAN ANTONIO — Metastatic breast cancer patients who received an oral formulation of the chemotherapy drug paclitaxel had better...
Long-term Follow-up Shows Estrogen Alone and Estrogen Plus Progestin Have Opposite Effects on Breast Cancer Incidence in Postmenopausal Women
Estrogen alone decreased, while adding progestin increased, breast cancer incidence SAN ANTONIO — Long-term follow-up results from two large,...
AACR Applauds Confirmation of Stephen M. Hahn, MD, as FDA Commissioner
Hahn has shown a commitment to science-directed and patient-focused policies PHILADELPHIA — The American Association for Cancer Research (AACR),...
MINDACT Trial Data Reveal Certain Women With Luminal Breast Cancer May Be Undertreated With Tamoxifen Alone
SAN ANTONIO — Among women with hormone receptor (HR)-positive, HER2-negative breast cancer with a high clinical risk (determined by tumor...
Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer
SAN ANTONIO — The addition of the anti-PD-L1 immunotherapeutic atezolizumab (Tecentriq) to neoadjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) did...
Breast Cancer Preventive Effects of Anastrozole Persist Long After Stopping Treatment
SAN ANTONIO — Breast cancer incidence among postmenopausal women at high risk for developing the disease continued to be...
Partial Breast Irradiation May be as Effective as Whole Breast Irradiation in Preventing Recurrence in Patients with Early Breast Cancer
10-year follow-up data supports earlier findings on recurrence and survival SAN ANTONIO — A 10-year follow-up study of breast...
Neoadjuvant Treatment with Pembrolizumab Improves Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer with Lymph Node Involvement
SAN ANTONIO — The addition of the anti-PD-1 immunotherapeutic pembrolizumab (Keytruda) to neoadjuvant chemotherapy increased the rates of pathologic complete response (pCR)...